AMGN Maintained by UBS -- Price Target Raised to $440
AMGN Maintained by UBS -- Price Target Raised to $440 GuruFocus
Covered in this story
What has happened since
- Amgen is down 1.2% since this was published, 60 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
UBS’s $440 target on $AMGN is on the record and being tracked to Aug 2027 (12-month default), scored on the close that day.
UBS’s track record →Analyst targets on Amgen
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
- Scotiabank: $408 → $450 by Aug 2027 · Outperform via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 50 stories mentioning Amgen, the earliest published 2 Jul 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.